Idelalisib: new targeted therapy improves outlook for patients with chronic lymphocytic leukaemia
NEW ORLEANS—A new oral tyrosine kinase inhibitor drug — idelalisib — has proved effective — and to have low toxicity — in patients with chronic lymphocytic leukaemia (CLL). Richard Furman MD from Weil
NEW ORLEANS—A new oral tyrosine kinase inhibitor drug — idelalisib — has proved effective — and to have low toxicity — in patients with chronic lymphocytic leukaemia (CLL). Richard Furman MD from Weill Cornell Medical College in New York announced findings at the American Society of Hematology Annual Meeting of a phase III, double blind, placebo-controlled study randomising patients to have idelalisib or placebo added to their rituximab treatment. He discussed the clinical implications with AudioMedica.com of the extension of both progression-free and overall survival among patients receiving the new agent in comparison with placebo. Jennifer Brown MD PhD, Director of the Chronic Lymphocytic Leukemia Center at the Dana-Farber Cancer Institute in Boston added her comments and explained why she considered idelalisib is a good candidate for early approval.
Tags
Related Episodes
Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”
Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome” An interview with: Hassan Mohammed Abushukair MD, Post-Doctoral Researcher, Oklahoma Univer
Othman Al-Sawaf MD PhD; ASH 2025: Fixed-Duration Targeted Combinations As Effective as Extended Monotherapy for Patients with Untreated Chronic Lymphocytic Leukemia
Othman Al-Sawaf MD PhD, a hematologist from University Hospital of Cologne, presents early data from the CLL17 international phase three trial at ASH 2025. The findings indicate that fixed-duration treatment with venetoclax plus obinutuzumab or venetoclax plus ibrutinib is non-inferior to continuous ibrutinib for patients with previously untreated chronic lymphocytic leukemia, potentially becoming the preferred treatment.
Erika Hamilton MD; 2025 SABCS: Small Molecule HER2 Inhibitor Tucatinib Improves Progression Free Survival in Patients with HER2-positive Metastatic Breast Cancer: in HER2CLIMB-05 Trial
This episode features an interview with Erika Hamilton MD at the 2025 San Antonio Breast Cancer Symposium (SABCS). Dr. Hamilton discusses findings from the HER2CLIMB-05 trial, showing that adding tucatinib to trastuzumab and pertuzumab significantly improves progression-free survival in patients with HER2-positive metastatic breast cancer as first-line maintenance therapy, with no new safety signals. This small molecule HER2 inhibitor offers a promising new option.